

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 9TH BOARD MEETING FOR FY2021

The board of directors (the “Board”) and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had on 25 October 2021 duly convened its 9th board meeting for the financial year ending 31 December 2021 (“FY2021”) by means of live meeting and telephone conference. The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were discussed and passed by the 8 directors out of the full board of 8 directors:

1. That, the proposed appointment of Ms. Zhang Mingrui (张铭芮) as a Director of the Company be approved.

Ms. Zhang Mingrui, born in November 1975, holds a Bachelor's Degree in Finance from Guiyang University of Finance and Economics (formerly known as Guiyang College of Finance and Economics), a Master of Business Administration Degree from Chongqing University and an Executive Master of Business Administration Degree from Hongkong University of Science and Technology. From January 2006 to March 2011, she held the position of General Manager of Taiji Group Sales Company (太极集团销售总公司). From March 2011 to May 2021, she served as Executive Deputy General Manager of Taiji Group Co., Ltd. (太极集团有限公司). Ms. Zhang had been a Director of Chongqing Taiji Industry (Group) Co., Ltd. (重庆太极实业(集团)股份有限公司) from May 2017 to July 2021. She had also served as Deputy General Manager of Chongqing Taiji Industry (Group) Co., Ltd. (重庆太极实业(集团)股份有限公司) for the period from May 2021 to July 2021. Since July 2021, Ms. Zhang has been working in Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“TPH”).

2. That, the proposed extension of time to perform the non-compete undertaking (details of which are as set out below) by the controlling shareholder of the Company, TPH, be approved.

TPH had previously undertaken that, in relation to the Company's sales business segment, TPH undertakes to transfer (either via share or asset sales) its subsidiaries that are in this segment to the Company or independent third parties by 31 December 2021, so as to ensure that TPH will no longer be in control of such subsidiaries. TPH now is requesting for an extension of time to fulfil the above undertaking by 31 December 2024 (the “**Proposed Extension**”). Please refer to the announcement dated 25 October 2021 made by the Company in relation to the Proposed Extension for further details.

Mr. Guo Min and Mr. Zhang Ping, being the interested directors, have abstained from voting on this resolution.

3. That, the line of credit granted to the Company to a limit of RMB1,300 million (the “**LOC**”) be approved.

The Board approved the LOC granted to the Company by Shanghai Pudong Development Bank Co., Ltd., with a term of one (1) year, and will be seeking a mandate from the shareholders at a general meeting of the Company to authorise the management of the Company to utilise the loan within the limit of the LOC based on the actual operational needs of the Company.

4. That, pursuant to the Company Law and the Articles of Association of the Company, the proposed convening of the 2nd extraordinary general meeting of the Company in 2021 (the “**2021 2nd EGM**”) be approved.

The above resolutions No. 1 to No. 3 shall be tabled for shareholders’ approval at the 2021 2nd EGM of the Company to be convened in due course.

By order of the Board

Jiao Yan
Secretary to the Board of Directors
25 October 2021